AstraZeneca的股票收益是投资者提振股权、分析师提升评级和收益比值估算的结果。 AstraZeneca's stock gains as investors boost stakes, analysts upgrade ratings, and earnings beat estimates.

AstraZeneca是一家生物制药公司,在第三和第四季度,若干机构投资者增加了在该公司的股份。 AstraZeneca, a biopharmaceutical company, saw several institutional investors increase their stakes in the company during the third and fourth quarters. 库存从UBS集团和德意志银行得到升级,分析家给出的平均目标价格为89.75美元。 The stock received upgrades from UBS Group and Deutsche Bank, with analysts giving it an average target price of $89.75. AstraZeneca报告每股收入为1.04美元,殴打估计数为0.03美元。 AstraZeneca reported earnings of $1.04 per share, beating estimates by $0.03. 该公司的投资组合包括Tagrisso、Imfinzi和Lynparza等药物。 The company's portfolio includes drugs like Tagrisso, Imfinzi, and Lynparza.